

RESEARCH

Early versus late initiation of GH replacement in adult-onset hypopituitarism

Mark R Postma¹, Pia Burman² and André P van Beek¹¹Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands²Department of Endocrinology, Skane University Hospital Malmö, University of Lund, Lund, SwedenCorrespondence should be addressed to A P van Beek: a.p.van.beek@umcg.nl

Abstract

Introduction: Adult-onset growth hormone deficiency (AGHD) is usually the last deficiency to be substituted in hypopituitarism. In children with documented GH deficiency, treatment without delay is crucial for achieving optimal effects on growth and development. In adults, it is not known whether a delay in treatment initiation influences biochemical response and the favourable physiological effects resulting from GH replacement therapy (GHRT).

Methods: A total of 1085 GH-deficient adults from KIMS (Pfizer International Metabolic Database) were included, adequately replaced with all pituitary hormones except for GH at baseline. Patients were stratified by sex and age (20–50 years and ≥ 50 years) and subsequently divided into two groups below and above the median duration of unsubstituted AGHD for that subgroup. The median time of unsubstituted GHD for the total cohort was 2.53 years (P5 = 0.35, P95 = 24.42).

Results: Beneficial effects of 4 years of GHRT were observed on lipids and quality of life in all subgroups. A decrease in waist circumference was observed only in older (>50 years) patients. There was no difference in IGF-I SDS and in GH dose required to normalize IGF-I in patients with a duration of unsubstituted AGHD above or below the median. No relevant differences were found between the groups for anthropometric measures, cardiovascular risk factors and quality of life scores.

Conclusion: In contrast to GHD in children and adolescents, no difference could be established in treatment response between early or late initiation of GHRT in AGHD in terms of required GH dose, IGF-I, metabolic health and quality of life.

Key Words

- ▶ adult-onset growth hormone deficiency
- ▶ growth hormone replacement therapy
- ▶ hypopituitarism
- ▶ treatment initiation

Endocrine Connections
(2020) 9, 687–695

Introduction

Adult growth hormone deficiency (AGHD) is characterized by changes in body fat distribution with increased central adiposity, hyperlipidaemia, increased predisposition to atherogenesis and reduced bone remodelling activity. It is also associated with a reduced quality of life. AGHD is usually caused by pituitary adenomas, recently also termed pituitary neuroendocrine tumours (PitNETs) (1), or the consequences of treatment of these tumours, including surgery and/or irradiation. It therefore usually occurs in the context of additional features of hypopituitarism,

compounding the clinical picture attributable to AGHD (2, 3). Available evidence shows benefit of GH replacement therapy (GHRT) on body composition, exercise capacity, bone health, several cardiovascular risk factors and quality of life (3, 4, 5). Pitfalls of GH and IGF-I assays and the recent upward adjustment of the normative IGF-I SD scores for the iSYS IGF-I assay make early recognition of AGHD increasingly difficult (6, 7, 8). It is not known whether these changes in SD scores and the likely association of delayed initiation of GHRT result in poorer outcomes.

In paediatric growth hormone therapy, it is well known that age of treatment onset is predictive of final height outcome (9). In addition, it has been shown that growth acceleration during the first year is more marked in younger children (10, 11). In adults, we and others previously demonstrated that age and sex influence body composition, both with respect to the effects of GHD (12, 13) and GHRT (14, 15).

Against this background, we studied whether there was a difference in response to GHRT between longer and shorter duration of unsubstituted AGHD in patients grouped by age and sex. We hypothesized that early initiation of GHRT in AGHD results in better responsiveness of the somatotrophic axis with higher increases in IGF-I, more favourable effects on metabolic health and better improvement of quality of life compared to late initiation.

Methods

Study population

The KIMS database (Pfizer International Metabolic Database) was used to study the effects of hypopituitarism on obesity. KIMS, initiated in 1994, is a pharmaco-epidemiological multicentre survey of adult hypopituitary (GH deficient) patients treated with GH replacement therapy (Genotropin®) (16). Included were all patients with a known duration of confirmed AGHD, defined as a peak GH level less than 3 µg/L mainly indicated by insulin-induced hypoglycaemia (in 76% of cases), but in other cases by a weaker GH stimulation test like the arginine (in 9%), GHRH (in 6%), glucagon (in 1%), or other tests (in 8%). Patients were adequately replaced with all pituitary hormones except for GH. Excluded were patients with a previous diagnosis of Cushing's disease, acromegaly and craniopharyngioma because these conditions are known to affect body composition, cardiovascular risk factors and quality of life. For similar reasons of confounding bias, females reported to be on oestrogen and females who got pregnant during the study time frame were excluded. Finally, patients exposed to radiotherapy (RT) and patients with unknown treatment for diagnoses in which RT is an option were excluded, as it was not possible to determine the exact duration of AGHD in these patients. The patient population consisted of patients with isolated AGHD as well as multiple pituitary hormone deficiencies. Patients included in this study started GH replacement therapy at entry into KIMS and were in follow-up for an average time of 4.0 years (s.d. 0.2 years). Patients who did not complete 4 years of follow-up were not included in the analyses.

With these criteria, a total of 1085 patients with hypopituitarism were identified for inclusion in the analysis. The KIMS countries (number of participants) for the present study were Argentina (12), Austria (19), Belgium (129), Switzerland (5), Czech Republic (31), Germany (304), Denmark (30), Spain (81), France (49), United Kingdom (97), Greece (7), Hungary (12), Ireland (12), Luxembourg (1), the Netherlands (81), Serbia (1), Sweden (184), Slovakia (9) and the United States (21).

Data were collected for KIMS at clinical visits on specially designed case record forms. The data collection process was externally monitored and audited. Demographic and clinical data related to pituitary and cardiovascular disease were used for the present analysis. The data collection into KIMS was approved by the Institutional Review Boards/Ethical Committees as required by local regulations in each participating country. Written informed consent was obtained from all patients before any data were entered into KIMS. The study was performed in accordance with The Declaration of Helsinki.

Estimated duration of unsubstituted AGHD

The estimated duration of unsubstituted AGHD was defined as time from the date of pituitary disease diagnosis as reported by local investigators to the date of entry into KIMS. In the rare event that the date of biochemical confirmation of AGHD was reported to be before the date of pituitary disease diagnosis, the date of biochemical confirmation was used. The median time of unsubstituted GHD for the total cohort was 2.53 years (P5=0.35, P95=24.42).

Stratification and definitions

Patients were stratified by sex and age (20–50 years and ≥50 years) and subsequently divided into two groups below and above the median duration of unsubstituted AGHD for that subgroup. The age at which a patient entered KIMS was chosen for stratification. Thus, a complete data set together with anthropometric measures and laboratory determinations was guaranteed. A provisional diagnosis of diabetes was defined on a single fasting plasma glucose level of 7.0 mmol/L or higher according to the American Diabetes Association criteria (17) or the use of antidiabetic drugs. The Seventh Report of the Joint Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) was used to define hypertension, i.e. a systolic blood pressure of more than 140 mmHg or

a diastolic blood pressure more than 90 mmHg or the use of antihypertensives (18).

Anthropometric measures

Height was measured with an accuracy of 0.5 cm and weight (in kilograms) to one decimal place. BMI was calculated from the formula: weight/height squared (kilograms per square meter). Waist circumference was measured in the supine position midway between the iliac crest and the lowest level of the thorax and hip as the maximal circumference. Blood pressure measurements in KIMS were standard office registrations.

Laboratory measurements

Measurements of serum total cholesterol (19), high-density lipoprotein (HDL) cholesterol (20), and triglycerides (21) were performed by standard methods according to the KIMS protocol. Lipids were measured centrally and serum low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald formula (22). Serum insulin-like growth factor I (IGF-I) was determined by RIA after acid/ethanol precipitation of IGF-binding proteins (Nichols Institute Diagnostics, San Juan Capistrano, CA, USA) until November 2002 and by chemiluminescence immunoassays from 2003 to 2004 (Nichols Advantage® System) and from 2005 to 2012 (Immulite 2500, DPC Siemens). For each assay, age- and gender-specific reference ranges were used to determine IGF-I SDS. Reference ranges and consistency of IGF-I SDS values between assays were validated internally. All above mentioned measurements were performed in a central laboratory. Glucose concentrations were measured in local participating centres. Whole blood concentrations were transformed to plasma values using an internally validated correction factor (23). All measurements including glucose were determined in fasting samples.

Quality of life assessment

Quality of life was assessed using the disease-specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA), a patient needs-based instrument developed specifically to detect deficits in areas that are affected in adults with GHD (24). The measure consists of 25 questions with 'yes' or 'no' response choices, with 'yes' answer indicating that the patient perceives a problem. The sum of 'yes' responses constitute a score, with a high score denoting a poor QoL. The QoL-AGHDA

demonstrated satisfactory psychometric properties across a wide range of languages (25).

Statistical analysis

All calculations were performed with SAS (version 9.4, SAS Institute Inc.) or SPSS 22.0 (SPSS) software. Data are reported as mean \pm s.d. or proportion, depending on type of variable. Males and females were analysed separately to avoid potential confounding by sex. For assessment of significance of mean differences between the patients below vs above the median for duration of unsubstituted AGHD, unpaired Student's *t*-tests were performed. If variances were tested unequal between populations, Satterthwaite's correction was applied. Comparisons of proportions were performed using the X^2 test. A two-sided *P* value <0.05 was considered to be significant.

Results

Baseline characteristics

Baseline characteristics of the GH deficient patients are shown in Table 1. The mean estimated duration of unsubstituted AGHD for the total cohort was 6.0 years (s.d. 8.2 years), of which 1.7 years (s.d. 3.8 years) were biochemically confirmed. The most prevalent diagnosis was pituitary adenoma. Most patients received surgery as primary treatment and had multiple other pituitary hormone deficiencies. ADH deficiency was less common in patients aged >50 years. Male patients had more ACTH and LH/FSH deficiency than females. Male patients with a duration of unsubstituted AGHD below the median received surgical treatment more often and had a significantly higher IGF-I SDS at baseline than those above the median. However, no difference was found between these groups in GH dose required to normalize IGF-I. Table 2 shows anthropometric measures, cardiovascular risk factors and quality of life scores for both sexes in the two age groups of patients at baseline.

Adequacy of hormonal substitution

Between 97 and 99% of patients with TSH and ACTH deficiency received adequate hormonal substitution both at baseline and after 4 years of GHRT. More than 95% of LH/FSH deficient males were treated with testosterone throughout this observational study. The prevalence of other pituitary deficiencies did not change after 4 years of GHRT (data not shown).

Table 1 Patient characteristics by sex and age cohort.

	Males				Females			
	20–49		>50		20–49		>50	
	<median	≥median	<median	≥median	<median	≥median	<median	≥median
Age cohort (y)	158	158	215	216	82	82	87	87
Median duration of unsubstituted AGHD (y)	2.37	2.37	2.56	2.56	2.57	2.57	3.06	3.06
Number	158	158	215	216	82	82	87	87
Duration of pituitary disease before GH start (y)	1.05 ± 0.60 ^c	9.12 ± 7.36	1.18 ± 0.63 ^c	10.82 ± 10.01	1.07 ± 0.66 ^c	9.90 ± 7.45	1.18 ± 0.71 ^c	14.46 ± 10.95
Diagnosis of AGHD								
Pituitary adenoma (%)	63	55	80	73	26 ^b	48	52	46
Other causes of acquired GHD (%)	26 ^a	38	14	19	56	45	40	41
Idiopathic GHD (%)	11	7	6	8	18 ^a	7	8	13
Isolated GHD (%)	9 ^b	2	5	4	15	10	6	5
Multiple pituitary hormone deficiencies (%)	91 ^b	98	95	96	85	90	94	95
Previous therapy								
Surgical treatment (%)	68 ^a	56	81 ^a	73	37	52	56	53
Pituitary hormone deficiencies								
TSH deficiency (%)	75	77	74	79	72	70	74 ^a	89
ACTH deficiency (%)	72	74	75	80	65	65	63	68
LH/FSH deficiency (%)	79 ^b	92	89	92	52	62	61	64
ADH deficiency (%)	26	30	15	17	18	30	14	17
GH treatment								
IGF-I SDS baseline	-1.64 ± 1.45 ^a	-2.14 ± 1.63	-1.3 ± 1.34 ^a	-1.74 ± 1.84	-1.91 ± 1.71	-2.19 ± 1.53	-1.37 ± 1.48	-1.56 ± 1.58
IGF-I SDS at 4 years	0.59 ± 1.26	0.24 ± 1.43	0.62 ± 1.2	0.67 ± 1.23	0.13 ± 1.21	-0.23 ± 1.21	0.81 ± 0.96	0.51 ± 1.21
Normal IGF-I (SDS -2 to 2) at 4 years (%)	89	88	87	85	90	90	95	89
Normal IGF-I (SDS -1 to 1) at 4 years (%)	51	53	47	49	63	59	49	55
GH starting dose (mg)	0.16 ± 0.12	0.18 ± 0.21	0.15 ± 0.17	0.17 ± 0.14	0.19 ± 0.15	0.18 ± 0.12	0.17 ± 0.15	0.14 ± 0.11
GH dose at 4 years (mg)	0.36 ± 0.24	0.4 ± 0.26	0.3 ± 0.22	0.33 ± 0.20	0.59 ± 0.43	0.5 ± 0.33	0.35 ± 0.23	0.32 ± 0.2

Data are given as numbers or percentages and mean ± s.d.

^a*p* < 0.05, ^b*p* < 0.01, ^c*p* < 0.001.

GH, growth hormone deficiency.



Table 2 Baseline anthropometric measures, cardiovascular risk factors and quality of life scores.

	Males				Females			
	20–49		≥50		20–49		≥50	
	<median	>median	<median	>median	<median	>median	<median	>median
Age cohort (y)								
Duration of unsubstituted GHD								
Number	158	158	215	216	82	82	87	87
Body composition								
BMI (kg/m ²)	28.4 ± 5	28.5 ± 5.3	29 ± 4.1	28.8 ± 4.4	28.6 ± 7.2	28.4 ± 6.1	30.6 ± 5.3^b	28.1 ± 4.5
Waist (cm)	99.9 ± 13	99.4 ± 13.6	104.1 ± 11^b	100.5 ± 11	88.5 ± 14.5	92.3 ± 16.1	97.8 ± 12.7	94.8 ± 11
Waist/hip-ratio	0.96 ± 0.09	0.95 ± 0.06	0.98 ± 0.06	0.97 ± 0.06	0.85 ± 0.09	0.88 ± 0.08	0.89 ± 0.06	0.91 ± 0.07
Blood pressure and hypertension								
Systolic BP (mmHg)	125 ± 16	124 ± 17	136 ± 18	135 ± 18	122 ± 16	123 ± 15	136 ± 23	132 ± 17
Diastolic BP (mmHg)	79 ± 11	79 ± 11	83 ± 10	82 ± 10	79 ± 11	79 ± 11	82 ± 11	79 ± 11
Hypertension - JCN 7 criteria (%)	22.2	20.3	52.6	45.4	20.7	14.6	48.3	47.1
Treatment of hypertension (%)	8.9^a	3.2	23.3	20.4	3.7	3.7	23	23
Glucose and diabetes								
Fasting plasma glucose (mmol/L)	4.80 ± 0.68	4.86 ± 1.39	5.11 ± 1.17	4.94 ± 0.73	5.12 ± 2.49	4.83 ± 0.64	5.12 ± 0.8	5.26 ± 1.14
Diabetes mellitus - IDF criteria (%)	4.4	7	7	6.5	11	2.4	16.1	12.6
Treatment of diabetes mellitus (%)	3.8	1.9	2.8	2.8	4.9	1.2	5.7	6.9
Lipids and treatment of dyslipidemia								
Total cholesterol (mmol/L)	5.8 ± 1.39	5.88 ± 1.15	5.81 ± 1.22	5.69 ± 1.09	5.74 ± 1.39	5.73 ± 0.93	6.2 ± 1.54	6.55 ± 1.25
HDL-cholesterol (mmol/L)	1.1 ± 0.33	1.13 ± 0.4	1.2 ± 0.38	1.17 ± 0.34	1.48 ± 0.37	1.44 ± 0.41	1.45 ± 0.49	1.29 ± 0.4
Triglycerides (mmol/L)	2.27 ± 1.27	2.64 ± 2.06	2.1 ± 1.11	2 ± 1.22	1.98 ± 2.09	1.92 ± 1.07	2.13 ± 1.06	2.12 ± 1.14
LDL-cholesterol (mmol/L)	3.71 ± 1.23	3.73 ± 1.02	3.67 ± 1.07	3.65 ± 0.97	3.32 ± 0.82	3.44 ± 0.87	3.73 ± 1.29^b	4.43 ± 1.16
Treatment of dyslipidemia (%)	5.7	8.2	12.1	13	4.9	4.9	12.6	10.3
Quality of life								
Mean weighted AGHDA score	10 ± 7.6	10 ± 7.1	8 ± 6.8	8.4 ± 6.4	10.8 ± 7.3	11.9 ± 7.2	12.1 ± 7.5	12.1 ± 7.3

Data are given as mean ± s.d.

^a*P* < 0.05, ^b*P* < 0.01.

AGHDA, assessment of growth hormone deficiency in adults; BP, blood pressure; IDF, International Diabetes Federation; JCN, Joint National Committee.



Effects of 4 years of GHRT

Beneficial effects of 4 years of GHRT were observed on lipids and quality of life in all subgroups. A decrease in waist circumference was observed only in older (>50 years) patients. Changes in those measures after 4 years of GHRT are shown in [Table 3](#).

Effects of early versus late initiation of GHRT

There was no difference in GH dose required to normalize IGF-I in patients with a duration of unsubstituted AGHD above or below the median. Additionally, IGF-I SDS did not differ between the early and late initiation groups after 4 years of GHRT.

Discussion

In this study, we investigated the effects of early versus late initiation of GHRT in adults with respect to GH dose, IGF-I, quality of life and metabolic health. Patients were grouped by age and sex, which are confounders known to influence the somatotrophic axis ([12](#), [13](#)). Four years of GHRT resulted in beneficial effects on lipids and quality of life in all cohorts. A decrease in waist circumference was observed only in the group of patients above 50 years of age. No differences were observed in GH dose required to normalize IGF-I between the groups with a duration of unsubstituted AGHD above or below the median. Additionally, IGF-I SDS did not differ between the groups after 4 years of GHRT. No relevant differences were found between the groups for anthropometric measures, cardiovascular risk factors and quality of life scores.

Our results are reassuring in relation to current clinical practice, in which AGHD is usually the last deficiency to be substituted in hypopituitarism. However, they are in contrast to the effects of paediatric growth hormone therapy, in which age of treatment onset is predictive of both growth acceleration during the first year and final height outcome ([9](#)). However, growth velocity in children is dependent on more hormonal and anabolic influences than GH *per se*, such as tempo of puberty and nutritional status.

For the initiation of postmenopausal oestradiol replacement therapy (ERT), it is now generally accepted that timing is critical; the sooner oestrogen is started after menopause, the greater the benefits ([26](#), [27](#)). These findings are presumed to be related to the health of the underlying tissue and/or to other factors such as

downregulation of receptors ([28](#), [29](#)). Whether a similar mechanism could be present in AGHD has not previously been addressed. Serum GH and IGF-I decrease with age, peaking at late adolescence and declining from age 20, resulting in considerably lower levels after age 60. This is likely to be the consequence of impaired signal transduction within the somatotrophic axis with age ([30](#), [31](#)). However, the results of this study indicate that the timing hypothesis does not apply to the somatotrophic axis, as late initiation of GHRT in AGHD did not result in less responsiveness. Oestradiol is a steroid hormone binding primarily to oestrogen receptors, nuclear proteins that bind to DNA and control gene expression, whereas GH binds to the membrane-bound GH receptor, activating several intra- and intercellular signal transduction pathways ([32](#)). The regulation of these different classes of receptors is inherently different and may contribute to the different findings.

Our study is prone to several shortcomings. First, the estimated duration of unsubstituted AGHD was defined as time from the date of pituitary disease diagnosis as reported by local investigators to the date of entry into KIMS. In the rare event that the date of biochemical confirmation of AGHD was reported to be before the date of pituitary disease diagnosis, the date of biochemical confirmation was used. Both definitions are proxies, but the date of biochemical confirmation is most often an underestimation of the actual duration of unsubstituted AGHD. Although the use of the date of pituitary disease diagnosis as starting point likely results in an overestimation of the actual duration of unsubstituted AGHD, the large contrast between short and long duration of unsubstituted AGHD as reported in this study is crucial to its analysis and provides a solid basis for its conclusions. Although dates of pituitary disease diagnosis were entered retrospectively at entry into KIMS, they were based on medical records and checked by a monitor, reducing the risk of obtaining incorrect information.

Secondly, although appropriate for a large epidemiological study, the use of BMI and waist circumference alone is not optimal to characterize body composition. Data on fat mass, fat-free mass, and bone mass are, however, not available in KIMS. Thirdly, a selection bias may be present by the exclusion of patients with co-morbidities and diabetes, although in recent years more patients with co-morbidities and diabetes were considered for GH replacement therapy, possibly reflecting increased knowledge and confidence in GH therapy gained with time ([33](#)).

Table 3 Changes in anthropometric measures, cardiovascular risk factors and quality of life scores after 4 years of GHRT.

	Males				Females			
	20-49		≥50		20-49		≥50	
	<median 158	>median 158	<median 215	>median 216	<median 82	>median 82	<median 87	>median 87
Age cohort (y)								
Duration of unsubstituted GHD Number								
Body composition								
Δ BMI (kg/m ²) – n=1033 (95)	0.7 ± 2.63	0.62 ± 2.71	0.24 ± 2.15	0.35 ± 1.79	0.71 ± 3.4	0.53 ± 2.72	0.03 ± 2.2	0 ± 2.62
Δ Waist (cm) – n=703 (65)	0.5 ± 7.51	0.46 ± 8.92	-0.5 ± 6.68	-0.11 ± 6.71	0.23 ± 8.51	0.95 ± 7.33	-0.9 ± 5.89	-1.43 ± 8.24
Δ Waist/hip-ratio – n=694 (64)	-0.01 ± 0.09	-0.01 ± 0.05	0 ± 0.06	-0.01 ± 0.06	0.02 ± 0.07	0.01 ± 0.07	0.02 ± 0.14	0.02 ± 0.14
Blood pressure								
Δ Systolic BP (mmHg) – n=959 (88)	2 ± 16	1 ± 15	0 ± 20	0 ± 18	2 ± 16	1 ± 15	0 ± 20	0 ± 18
Δ Diastolic BP (mmHg) – n=959 (88)	2 ± 11	-1 ± 12	-1 ± 12	-1 ± 11	-2 ± 11	1 ± 13	-2 ± 11	-2 ± 13
Glucose								
Δ Fasting plasma glucose (mmol/L) – n=442 (41)	0.43 ± 1.8	0.36 ± 0.87	0.27 ± 0.98	0.27 ± 1.04	-0.12 ± 2.9	0.24 ± 0.91	0.44 ± 1.1	0.37 ± 1.2
Lipids								
Δ Total cholesterol (mmol/L) – n=418 (39)	-0.75 ± 1.45	-0.28 ± 1.07	-0.72 ± 1.06	-0.47 ± 0.88	-0.45 ± 1.37	-0.3 ± 0.87	-0.58 ± 1.51	-0.71 ± 1.53
Δ HDL-cholesterol (mmol/L) – n=418 (39)	0.08 ± 0.26	0.05 ± 0.21	-0.03 ± 0.35	0.06 ± 0.26	0.03 ± 0.33	-0.1 ± 0.28	-0.05 ± 0.33	0.07 ± 0.34
Δ Triglycerides (mmol/L) – n=418 (39)	-0.27 ± 1.26	-0.1 ± 1.21	-0.14 ± 0.88	-0.29 ± 1.2	-0.14 ± 2.21	-0.02 ± 1.14	-0.26 ± 0.86	0.01 ± 0.58
Δ LDL-cholesterol (mmol/L) – n=392 (36)	-0.7 ± 1.26	-0.32 ± 0.99	-0.58 ± 0.93	-0.42 ± 0.78	-0.33 ± 0.67	-0.19 ± 0.66	-0.37 ± 1.33	-0.78 ± 1.36
Quality of life								
Δ Mean weighted AGHDA score – n=548 (51)	-3.8 ± 5.2	-3.9 ± 6.7	-3.3 ± 5	-2.9 ± 4.7	-3.8 ± 4.7	-3.2 ± 5.5	-5.2 ± 7	-4.7 ± 5.7

Data are given as mean ± s.d. (note that no significant differences were found). AGHDA, assessment of growth hormone deficiency in adults; BP, blood pressure; n, number of patients with available data (percentage of total 1085); Δ, delta.



Finally, one could argue that male patients below the median for duration of unsubstituted GHD receiving surgical treatment more often constitutes confounding by indication, as patients who receive surgical treatment are generally in follow-up according to protocol, are tested for hypopituitarism regularly and therefore have a higher chance to get GHRT early. However, this potential bias did not result in a difference between these groups in GH dose required to normalize IGF-I, nor in a difference in treatment response.

In conclusion, in contrast to GHD in children and adolescents, no difference could be established in treatment response between early or late initiation of GHRT in AGHD in terms of required GH dose, IGF-I, metabolic health and quality of life.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

M R P is a recipient of the Pfizer ASPIRE Young Investigator Research Awards in Endocrinology. P B and A P v B are members of the KIMS Steering Committee and have received consulting fees from Pfizer.

Acknowledgements

The authors express their thanks to the KIMS investigators in general and to Anders F Mattsson in particular, who provided the patient data. KIMS is sponsored by Pfizer.

References

- Asa SL, Casar-Borota O, Chanson P, Delgrange E, Earls P, Ezzat S, Grossman A, Ikeda H, Inoshita N, Karavitaki N, *et al.* From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. *Endocrine-Related Cancer* 24 C5–C8. (<https://doi.org/10.1530/ERC-17-0004>)
- Feldt-Rasmussen U & Klose M. Adult growth hormone deficiency clinical management. *Endotext*. South Dartmouth, MA, USA: MDText.com, Inc., 2017. (available at: <https://www.ncbi.nlm.nih.gov/books/NBK425701/>)
- Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML & Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology and Metabolism* 2011 96 1587–1609. (<https://doi.org/10.1210/jc.2011-0179>)
- Bollerslev J, Ueland T, Jorgensen AP, Fougner KJ, Wergeland R, Schreiner T & Burman P. Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. *European Journal of Endocrinology* 2006 154 537–543. (<https://doi.org/10.1530/eje.1.02125>)
- Hazem A, Elamin MB, Bancos I, Malaga G, Prutsky G, Domecq JP, Elraiyah TA, Abu Elnour NO, Prevost Y, Almandoz JP, *et al.* Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. *European Journal of Endocrinology* 2012 166 13–20. (<https://doi.org/10.1530/EJE-11-0558>)
- Junnilla RK, Strasburger CJ & Bidlingmaier M. Pitfalls of insulin-like growth factor-I and growth hormone assays. *Endocrinology and Metabolism Clinics of North America* 2015 44 27–34. (<https://doi.org/10.1016/j.ecl.2014.10.003>)
- Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, Korner A, Obermayer-Pietsch B, Hubener C, Dahlgren J, *et al.* Reference intervals for insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. *Journal of Clinical Endocrinology and Metabolism* 2014 99 1712–1721. (<https://doi.org/10.1210/jc.2013-3059>)
- Varewijck AJ, Lamberts SW, van der Lely AJ, Neggers SJ, Hofland LJ & Janssen JA. The introduction of the IDS-iSYS total IGF-1 assay may have far-reaching consequences for diagnosis and treatment of GH deficiency. *Journal of Clinical Endocrinology and Metabolism* 2015 100 309–316. (<https://doi.org/10.1210/jc.2014-2558>)
- Wit JM, Deeb A, Bin-Abbas B, Al Mutair A, Koledova E & Savage MO. Achieving optimal short- and long-term responses to paediatric growth hormone therapy. *Journal of Clinical Research in Pediatric Endocrinology* 2019 11 329–340. (<https://doi.org/10.4274/jcrpe.galenos.2019.2019.0088>)
- Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K & Price DA. Derivation and validation of a mathematical model for predicting the response to exogenous recombinant human growth hormone (GH) in prepubertal children with idiopathic GH deficiency. KIGS International Board. Kabi Pharmacia International Growth Study. *Journal of Clinical Endocrinology and Metabolism* 1999 84 1174–1183. (<https://doi.org/10.1210/jcem.84.4.5634>)
- Ranke MB, Lindberg A, Price DA, Darendeliler F, Albertsson-Wikland K, Wilton P, Reiter EO & KIGS International Board. Age at growth hormone therapy start and first-year responsiveness to growth hormone are major determinants of height outcome in idiopathic short stature. *Hormone Research* 2007 68 53–62. (<https://doi.org/10.1159/000098707>)
- Pijl H, Langendonk JG, Burggraaf J, Frolich M, Cohen AF, Veldhuis JD & Meinders AE. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. *Journal of Clinical Endocrinology and Metabolism* 2001 86 5509–5515. (<https://doi.org/10.1210/jcem.86.11.8061>)
- van Beek AP, Wolffenbuttel BH, Runge E, Trainer PJ, Jonsson PJ & Koltowska-Haggstrom M. The pituitary gland and age-dependent regulation of body composition. *Journal of Clinical Endocrinology and Metabolism* 2010 95 3664–3674. (<https://doi.org/10.1210/jc.2009-2506>)
- Burman P, Johansson AG, Siegbahn A, Vessby B & Karlsson FA. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women. *Journal of Clinical Endocrinology and Metabolism* 1997 82 550–555. (<https://doi.org/10.1210/jcem.82.2.3776>)
- Postma MR, van Beek AP, Jonsson PJ, van Bunderen CC, Drent ML, Mattsson AF & Camacho-Hubner C. Improvements in body composition after 4 years of growth hormone treatment in adult-onset hypopituitarism compared to age-matched controls. *Neuroendocrinology* 2019 109 131–140. (<https://doi.org/10.1159/000499430>)
- Abs R, Bengtsson BA, Hernberg-Stahl E, Monson JP, Tauber JP, Wilton P & Wüster C. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. *Clinical Endocrinology* 1999 50 703–713. (<https://doi.org/10.1046/j.1365-2265.1999.00695.x>)
- Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. *Diabetes Care* 2003 26 (Supplement 1) S5–S20. (<https://doi.org/10.2337/diacare.26.2007.s5>)

- 18 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, *et al.* The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003 **289** 2560–2572. (<https://doi.org/10.1001/jama.289.19.2560>)
- 19 Lie RF, Schmitz JM, Pierre KJ & Gochman N. Cholesterol oxidase-based determination, by continuous-flow analysis, of total and free cholesterol in serum. *Clinical Chemistry* 1976 **22** 1627–1630. (<https://doi.org/10.1093/clinchem/22.10.1627>)
- 20 Lopes-Virella MF, Stone P, Ellis S & Colwell JA. Cholesterol determination in high-density lipoproteins separated by three different methods. *Clinical Chemistry* 1977 **23** 882–884. (<https://doi.org/10.1093/clinchem/23.5.882>)
- 21 Fossati P & Prencipe L. Serum triglycerides determined colorimetrically with an enzyme that produces hydrogen peroxide. *Clinical Chemistry* 1982 **28** 2077–2080. (<https://doi.org/10.1093/clinchem/28.10.2077>)
- 22 Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clinical Chemistry* 1972 **18** 499–502. (<https://doi.org/10.1093/clinchem/18.6.499>)
- 23 Burnett RW, D'Orazio P, Fogh-Andersen N, Kuwa K, Kulpmann WR, Larsson L, Lewnstaam A, Maas AH, Mager G, Spichiger-Keller U, *et al.* IFCC recommendation on reporting results for blood glucose. *Clinica Chimica Acta* 2001 **307** 205–209. ([https://doi.org/10.1016/s0009-8981\(01\)00431-4](https://doi.org/10.1016/s0009-8981(01)00431-4))
- 24 McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L & Wiren L. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. *Quality of Life Research* 1999 **8** 373–383. (<https://doi.org/10.1023/a:1008987922774>)
- 25 McKenna S & Doward L. Measuring quality of life in adults with growth hormone deficiency. *Clinical Endocrinology* 1996 **45** 507–508. (<https://doi.org/10.1046/j.1365-2265.1996.t01-3-00826.x>)
- 26 Speth RC, D'Ambra M, Ji H & Sandberg K. A heartfelt message, estrogen replacement therapy: use it or lose it. *American Journal of Physiology: Heart and Circulatory Physiology* 2018 **315** H1765–H1778. (<https://doi.org/10.1152/ajpheart.00041.2018>)
- 27 Hodis HN, Mack WJ, Henderson VW, Shoupe D, Budoff MJ, Hwang-Levine J, Li Y, Feng M, Dustin L, Kono N, *et al.* Vascular effects of early versus late postmenopausal treatment with estradiol. *New England Journal of Medicine* 2016 **374** 1221–1231. (<https://doi.org/10.1056/NEJMoa1505241>)
- 28 Hodis HN & Mack WJ. The timing hypothesis and hormone replacement therapy: a paradigm shift in the primary prevention of coronary heart disease in women. Part 2: comparative risks. *Journal of the American Geriatrics Society* 2013 **61** 1011–1018. (<https://doi.org/10.1111/jgs.12281>)
- 29 Hodis HN, Mack WJ, Shoupe D, Azen SP, Stanczyk FZ, Hwang-Levine J, Budoff MJ & Henderson VW. Methods and baseline cardiovascular data from the early versus late intervention trial with estradiol testing the menopausal hormone timing hypothesis. *Menopause* 2015 **22** 391–401. (<https://doi.org/10.1097/GME.0000000000000343>)
- 30 Zadik Z, Chalew SA, McCarter Jr RJ, Meistas M & Kowarski AA. The influence of age on the 24-hour integrated concentration of growth hormone in normal individuals. *Journal of Clinical Endocrinology and Metabolism* 1985 **60** 513–516. (<https://doi.org/10.1210/jcem-60-3-513>)
- 31 Xu X, Bennett SA, Ingram RL & Sonntag WE. Decreases in growth hormone receptor signal transduction contribute to the decline in insulin-like growth factor I gene expression with age. *Endocrinology* 1995 **136** 4551–4557. (<https://doi.org/10.1210/endo.136.10.7664676>)
- 32 Dehkhoda F, Lee CMM, Medina J & Brooks AJ. The growth hormone receptor: mechanism of receptor activation, cell signaling, and physiological aspects. *Frontiers in Endocrinology* 2018 **9** 35. (<https://doi.org/10.3389/fendo.2018.00035>)
- 33 Hoybye C, Burman P, Feldt-Rasmussen U, Hey-Hadavi J, Aydin F, Camacho-Hubner C & Mattsson AF. Change in baseline characteristics over 20 years of adults with growth hormone (GH) deficiency on GH replacement therapy. *European Journal of Endocrinology* 2019 **181** 629–638. (<https://doi.org/10.1530/EJE-19-0576>)

Received in final form 8 June 2020

Accepted 18 June 2020

Accepted Manuscript published online 19 June 2020